ArticleMolecular biology reports2026
Phytochemical profiling and biological evaluation of hazelnut shell extract reveals neuroprotective potential in human microglial cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurotoxicity and chronic neuroinflammation are complex pathological processes involving the overactivation of microglia, which can lead to functional impairments in the central nervous system. This study aimed to characterize the phytochemical profile of the aqueous extract of hazelnut shell (Corylus avellana) an agricultural by-product, and to evaluate its neuroprotective potential comprehensively in the human microglial cell line (HMC-3). METHODS AND
resultsLiquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis revealed that the extract contained several phenolic compounds, with quinic acid (2602.88 µg/g), chlorogenic acid (1583.80 µg/g), and gallic acid (983.50 µg/g) being the predominant constituents. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) and Lactate dehydrogenase (LDH) release assays conducted on HMC-3 cells revealed that concentrations of up to 62.5 µg/mL-maintained cell viability above 70%, effectively preserving metabolic activity and membrane integrity. Quantitative analysis of inflammatory markers revealed that the extract significantly suppressed the levels of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α (p < 0.05). Regarding oxidative balance, total oxidant status (TOS) remained stable while total antioxidant capacity (TAC) increased significantly, particularly at 400 µg/mL (0.914 ± 0.146 mmol Trolox Eq/L). Furthermore, antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa was confirmed at various concentrations via disk diffusion and optical density methods.
conclusionThe hazelnut shell extract is a promising natural biocomponent for regulating neuroinflammation and developing neuroprotective strategies due to the anti-inflammatory and antioxidant effects of its bioactive compounds.
Indexed as
Identifiers
41995931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.